Clinical trials: Dermatologic Diseases
Male Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
This phase I trial is studying the side effects and best dose of alvespimycin hydrochloride in treating patients with metastatic or unresectable solid tumors.
- Conditions
- Male Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Breast Cancer
- Trial name
- NCT00089362
- Testing
- alvespimycin hydrochloride, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancers, Liver Cancer
AI-Assisted Non-Contrast CT for Multi-Cancer Screening
Cancer poses a major public health challenge in China. Early detection can improve treatment outcomes and survival rates. In this study, we will conduct a large-scale, prospective, multi-center cohort study to evaluate the…
- Conditions
- Lung Cancers, Liver Cancer, Gastric Cancers, Colorectal, Cancer
- Trial name
- NCT06632886
- Testing
- AI-Assisted Non-Contrast CT for Multi-Cancer Screening
- Where
- China
- Volunteers
- 1,000,000 people, healthy volunteers welcome
- Sponsor
- Guo ShiWei
Pruritus, Pregnancy Related
Treatment of Pruritus With Intramuscular Promethazine
Neuraxial narcotics are commonly used in obstetric patients for cesarean delivery to help with pain control over the first 24 hours after the surgery.
- Trial name
- NCT04805073
- Testing
- Promethazine
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University of Florida
Cholestasis, Intrahepatic Cholestasis of Pregnancy
Investigation of the Pruritogens of Liver-related Diseases
This study hopes investigate the itch-inducing ability of different potential pruritogen candidates of cholestasis pruritus, especially the intrahepatic cholestasis of pregnancy (ICP).
- Trial name
- NCT06364969
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Peking University
Scleroderma
A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma
To evaluate the safety and tolerability of a multiple-dosed drug (MEDI-546) in adults with scleroderma.
- Trial name
- MEDI-546 (NCT00930683)
- Testing
- MEDI-546
- Where
- 11 sites in United States
- Volunteers
- 34 people
- Sponsor
- MedImmune LLC
Breast Cancer
Chemotherapy-Induced Peripheral Neuropathy - Additional Evaluation in Breast Cancer Survivors
The main goal of this trial is to identify the optimal cut-off score of a Scoring System to discriminate between mild chemotherapy-induced peripheral neuropathy (CIPN) and no CIPN in breast cancer survivors previously treated…
- Trial name
- NEURO-BREAC-02 (NCT07604441)
- Testing
- Symptom-based scoring system
- Where
- Germany
- Volunteers
- 28 people
- Sponsor
- University Hospital Schleswig-Holstein
Breast Cancer
Effectiveness of Cryotherapy Combined With Compression Therapy for Preventing Chemotherapy-induced Peripheral Neuropathy
This is a prospective, multi-center, randomized study designed to evaluate the clinical efficacy of cryotherapy combined with compression therapy in preventing albumin-paclitaxel induced peripheral neuropathy.
- Trial name
- NCT05341141
- Testing
- Frozen glove and sock, ddEC-ddT
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Peking University
Alopecia Areata
Sodium Valproate-loaded Nanospanlastics in Patchy Alopecia Areata in Comparison to Topical Steroids
the aim of this study is to assess the efficacy and safety of sodium valproate-loaded nanospanlastic in the treatment of patchy AA, in comparison to conventional therapy with topical steroids
- Trial name
- NCT05017454
- Testing
- the optimized sodium valproate-loaded nanospanlastic dispersion, mometasone furoate lotion
- Where
- Egypt
- Volunteers
- 67 people
- Sponsor
- Kasr El Aini Hospital
Diabetic Foot Ulcer (DFU), Venous Leg Ulcer (VLU)
Safety and Preliminary Efficacy of TrophiPatch, an Adipose-Derived Stromal Cell Patch for Chronic Leg Ulcers
This study aims to evaluate the safety and effectiveness of an experimental biological dressing called TrophiPatch, applied to adults with chronic leg ulcers of diabetic or vascular orign.
- Trial name
- RESCUE-PATCH (NCT07048054)
- Testing
- TrophiPatch: allogeneic adipose-derived stromal cell patch
- Where
- Switzerland
- Volunteers
- 18 people
- Sponsor
- Nicolò Brembilla
Breast Cancer
Super-Resolution Ultrasound Microvascular Mapping for Non-Invasive Breast Cancer Molecular Subtyping: A Validated Nomogram
Purpose: This study aims to develop a non-invasive method to distinguish between luminal and non-luminal breast cancer subtypes using super-resolution ultrasound (SRUS).
- Trial name
- SRUS-Map (NCT07581054)
- Testing
- Not applicable- observational study
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Anhui Provincial Cancer Hospital
Psoriasis
The Effect of NB-UVB on Interleukin-36 Levels in Psoriasis
Psoriasis is an immune-mediated skin disease that affects 1-2 % of the population. Several cytokines have been found to be involved in the complex pathogenesis of this disease.
- Trial name
- NCT03526705
- Testing
- NB-UVB
- Volunteers
- 25 people
- Sponsor
- Cairo University
Breast Cancer, Colon Cancer
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
This pilot clinical trial studies copper Cu 64 anti-carcinoembryonic antigen (CEA) monoclonal antibody M5A positron emission tomography (PET) in diagnosing patients with CEA positive cancer.
- Conditions
- Breast Cancer, Colon Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT02293954
- Testing
- radionuclide imaging, positron emission tomography, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Pyoderma Gangrenosum
Autologous Platelet-Rich Plasma Therapy in the Treatment of Pyoderma Gangrenosum
Pyoderma gangrenosum (PG) is a chronic inflammatory condition with severe painful ulcers. We hypothesize that Platelet-rich plasma(PRP) therapy derived from patient's own blood has a high concentration of endogenous growth…
- Trial name
- NCT05984654
- Testing
- Platelet rich plasma therapy
- Where
- United States
- Sponsor
- Ohio State University
Systemic Sclerosis
RElevance of UltraSonography for Assessing Salivary Gland Involvement in Systemic Sclerosis (SSc)
As fibrosis of salivary glands is supposed to be the main mechanism involved in Systemic sclerosis (SSc)-associated sicca syndrome, Ultrasonography , biopsy and measuring gland elasticity (by ARFI (Acoustic Radiation Force…
- Trial name
- REUSSI-SSc (NCT04001556)
- Testing
- Minor Salivary gland Biopsy, ARFI, MSG US
- Where
- 3 sites in France
- Volunteers
- 75 people
- Sponsor
- Rennes University Hospital
Metastatic Solid Tumor, Ovarian Cancer
Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors
This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN818 with Olaparib in adult patients with locally advanced or metastatic solid tumors
- Conditions
- Metastatic Solid Tumor, Ovarian Cancer, Breast Cancer, BRCA 1 /2 and / or HRD
- Trial name
- NCT07156253
- Testing
- SYN818 and Olaparib will be administered
- Where
- 2 sites in China
- Volunteers
- 110 people
- Sponsor
- Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
Psoriasis
A Study to Evaluate Remicade (Infliximab) in Moderate-to-Severe Chronic Plaque Psoriasis in the Middle Eastern Population (Study P04528)
Middle Eastern subjects with moderate-to-severe chronic plaque psoriasis will be administered infusions of infliximab (Remicade) at 5 mg/kg of body weight at Weeks 0, 2, 6, 14, and 22.
- Trial name
- NCT00687362
- Testing
- Infliximab
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Pilot Study to Determine Radioiodide Accumulation and Dosimetry in Breast Cancers Using 124I PET/CT
This is a pilot imaging study for women whose tumors express NIS [Na+I- symporter, sodium iodide symporter]. Eligibility is limited to the presence of strong (3+) and/or plasma membrane staining in > 20% of cells as determined by…
- Conditions
- Breast Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3), Breast Cancer Metastatic Breast Cancer
- Trial name
- NCT00725946
- Testing
- Iodine-124, PET/CT with Iodine-124
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Stanford University
Dermatitis, Seborrheic
STUDY TO ASSESS THE LONG-TERM SAFETY OF EXTINA (KETOCONAZOLE) FOAM, 2%
Extina (ketoconazole) Foam, 2% was approved for marketing in the United States (US) in June 2007. Extina foam is indicated for topical treatment of seborrheic dermatitis in immunocompetent patients 12 years of age and older.
- Trial name
- NCT00703846
- Testing
- Ketoconazole
- Volunteers
- 498 people
- Sponsor
- Stiefel, a GSK Company
Head and Neck Cancer, Breast Cancer
Evaluation of Improved Onboard Patient Imaging
The primary objective of radiation therapy is to deliver a therapeutic dose of radiation precisely to the target while minimizing exposure to healthy surrounding tissues.
- Conditions
- Head and Neck Cancer, Breast Cancer, Upper Gastrointestinal Cancer, Lung Cancer
- Trial name
- NCT06187103
- Testing
- HyperSight Imaging
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Varian, a Siemens Healthineers Company
Giant Cell Arteritis
Giant Cell Arteritis Treatment With Ultra-short Glucocorticoids and Tocilizumab
Two recent RCTs showed the ability of tocilizumab to induce and maintain remission of giant cell arteritis. Both studies used the dosing schemes for Rheumatoid Arthritis (i.e. 8mg/kg bodyweight i.v.
- Trial name
- GUSTO (NCT03745586)
- Testing
- Tocilizumab, Glucocorticoids
- Where
- Switzerland
- Volunteers
- 18 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.